VJHemOnc is committed to improving our service to you

ASH 2019 | Ibrutinib and rituximab shows superior PFS vs. FCR in CLL

VJHemOnc is committed to improving our service to you

Jacqueline Barrientos

Jacqueline Barrientos, MD, Northwell Health, New York, NY, discusses the extended follow-up results from the E1912 trial (NCT02048813) comparing chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) to the combination of ibrutinib and rituximab (IR) for previously untreated chronic lymphocytic leukemia (CLL) patients. With extended follow-up, the combination of ibrutinib and rituximab continues to provide superior progression-free survival compared to FCR for younger patients with previously untreated CLL. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter